DE69229254T2 - Verfahren zur Herstellung von menschlichen Lymphozyten und menschlichen Antikörpern; und so hergestellte Antikörper - Google Patents

Verfahren zur Herstellung von menschlichen Lymphozyten und menschlichen Antikörpern; und so hergestellte Antikörper

Info

Publication number
DE69229254T2
DE69229254T2 DE69229254T DE69229254T DE69229254T2 DE 69229254 T2 DE69229254 T2 DE 69229254T2 DE 69229254 T DE69229254 T DE 69229254T DE 69229254 T DE69229254 T DE 69229254T DE 69229254 T2 DE69229254 T2 DE 69229254T2
Authority
DE
Germany
Prior art keywords
antibodies
human
processes
produced
production
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69229254T
Other languages
English (en)
Other versions
DE69229254D1 (de
Inventor
Toshio Kudo
Shuichi Hiyamuta
Toshiyuki Tanedani
Akihiko Kadota
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Idemitsu Kosan Co Ltd
Original Assignee
Idemitsu Kosan Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP4244250A external-priority patent/JPH05304988A/ja
Application filed by Idemitsu Kosan Co Ltd filed Critical Idemitsu Kosan Co Ltd
Application granted granted Critical
Publication of DE69229254D1 publication Critical patent/DE69229254D1/de
Publication of DE69229254T2 publication Critical patent/DE69229254T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
    • A01K67/027—New breeds of vertebrates
    • A01K67/0271—Chimeric animals, e.g. comprising exogenous cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0381—Animal model for diseases of the hematopoietic system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
DE69229254T 1991-10-30 1992-10-29 Verfahren zur Herstellung von menschlichen Lymphozyten und menschlichen Antikörpern; und so hergestellte Antikörper Expired - Fee Related DE69229254T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP31166591 1991-10-30
JP7018792 1992-02-20
JP4244250A JPH05304988A (ja) 1992-02-20 1992-08-20 抗ｈｄモノクローナル抗体及びそれを産生する細胞株

Publications (2)

Publication Number Publication Date
DE69229254D1 DE69229254D1 (de) 1999-07-01
DE69229254T2 true DE69229254T2 (de) 1999-09-23

Family

ID=27300259

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69229254T Expired - Fee Related DE69229254T2 (de) 1991-10-30 1992-10-29 Verfahren zur Herstellung von menschlichen Lymphozyten und menschlichen Antikörpern; und so hergestellte Antikörper

Country Status (3)

Country Link
US (2) US5681729A (de)
EP (1) EP0539970B1 (de)
DE (1) DE69229254T2 (de)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5550020A (en) * 1994-07-08 1996-08-27 Visible Genetics Inc. Method, reagents and kit for diagnosis and targeted screening for retinoblastoma
US5783186A (en) * 1995-12-05 1998-07-21 Amgen Inc. Antibody-induced apoptosis
AU9374198A (en) * 1997-09-08 1999-03-29 Idec Pharmaceuticals Corporation Methods for producing human antibodies in scid mice using dendritic cells
CA2333147C (en) 1998-07-13 2012-02-07 Board Of Regents, The University Of Texas System Cancer treatment methods using antibodies to aminophospholipids
US6794494B1 (en) 2003-04-14 2004-09-21 Arius Research, Inc. Cancerous disease modifying antibodies
US20080124327A1 (en) * 1999-10-08 2008-05-29 Arius Research, Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US7419792B2 (en) * 1999-10-08 2008-09-02 Arius Research Inc. Laminin Receptor 1 Precursor Protein (37LRP) epitope delineated by an Hepatocellular carcinoma specific antibody
US7947496B2 (en) * 1999-10-08 2011-05-24 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US7256271B2 (en) 2003-01-21 2007-08-14 Arius Research Inc. Cancerous disease modifying antibodies
US7252821B2 (en) 1999-10-08 2007-08-07 Arius Research Inc. Cancerous disease modifying antibodies
US8071072B2 (en) * 1999-10-08 2011-12-06 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US6657048B2 (en) * 1999-10-08 2003-12-02 Arius Research, Inc. Individualized anti-cancer antibodies
US20040105816A1 (en) * 1999-10-08 2004-06-03 Young David S. F. Cancerous disease modifying antibodies
US7442776B2 (en) * 1999-10-08 2008-10-28 Young David S F Cancerous disease modifying antibodies
US6180357B1 (en) * 1999-10-08 2001-01-30 Arius Research, Inc. Individualized patient-specific anti-cancer antibodies
US20090004103A1 (en) * 1999-10-08 2009-01-01 Young David S F Cytotoxicity mediation of cells evidencing surface expression of CD44
US8048416B2 (en) 1999-10-08 2011-11-01 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US7189397B2 (en) * 1999-10-08 2007-03-13 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US20040001789A1 (en) * 1999-10-08 2004-01-01 Young David S. F. Cytotoxicity mediation of cells evidencing surface expression of gp96 or precursors thereof
US20050100542A1 (en) * 1999-10-08 2005-05-12 Young David S. Cytotoxicity mediation of cells evidencing surface expression of CD44
US7534429B2 (en) * 2000-11-29 2009-05-19 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD63
US20060210474A1 (en) * 2000-11-29 2006-09-21 Young David S Cytotoxicity mediation of cells evidencing surface expression of CD63
US7361343B2 (en) * 2003-01-21 2008-04-22 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of CD63
US7009040B2 (en) * 2003-01-21 2006-03-07 Arius Research, Inc. Cancerous disease modifying antibodies
US7431923B2 (en) * 2005-01-03 2008-10-07 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of CD63
US7442777B2 (en) * 2000-11-29 2008-10-28 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of CD63
ES2358730T3 (es) 2002-07-15 2011-05-13 Board Of Regents, The University Of Texas System Anticuerpos seleccionados y péptidos de duramicina que se enlazan a fosfolípidos aniónicos y aminofosfolípidos y sus usos en el tratamiento de infecciones virales y del cáncer.
EP1565571B1 (de) 2002-11-19 2014-01-08 CLLUONE Diagnostics A/S Verfahren zur diagnose der chronischen lymphatischen b-zell leukämie (b-cll)
US7488475B2 (en) 2003-01-21 2009-02-10 Arius Research, Inc. Antibody therapy of tumors
US7393531B2 (en) * 2003-01-21 2008-07-01 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of MCSP
US7175846B2 (en) * 2003-01-21 2007-02-13 Arius Research Inc. Cancerous disease modifying antibodies
US7468254B2 (en) * 2003-01-21 2008-12-23 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of MCSP
US7361342B2 (en) * 2003-01-21 2008-04-22 Arius Research Inc. Cancerous disease modifying antibodies
EP1597367B1 (de) * 2003-02-19 2010-07-07 Novartis AG In metastatischen menschlichen tumorzellen exprimiertes glycoproteinantigen sima135
US20080213169A1 (en) * 2003-04-14 2008-09-04 Arius Research, Inc. Cytotoxicity mediation of cells evidencing surface expression of CD59
US7195764B2 (en) 2003-04-14 2007-03-27 Arius Research Inc. Cancerous disease modifying antibodies
US7399835B2 (en) * 2004-02-26 2008-07-15 Arius Research Inc. Cancerous disease modifying antibodies
AU2004231094A1 (en) * 2003-04-14 2004-10-28 Board Of Regents, The University Of Texas System Methods for ex vivo hybridoma-free production of polyclonal and monoclonal antibodies and generation of immortalized cell populations
US20080025977A1 (en) * 2003-04-14 2008-01-31 Arius Research, Inc. Cytotoxicity mediation of cells evidencing surface expression of CD59
US20060140963A1 (en) * 2003-04-14 2006-06-29 Arius Research, Inc. Cytotoxicity mediation of cells evidencing surface expression of CD59
US20050027106A1 (en) * 2003-07-28 2005-02-03 Young David S. F. Cancerous disease modifying antibodies
US7348413B2 (en) * 2004-02-26 2008-03-25 Arius Research Inc. Cancerous disease modifying antibodies
US20050255041A1 (en) * 2004-05-13 2005-11-17 Arius Research, Inc. Cancerous disease modifying antibodies
US7394210B2 (en) * 2004-09-29 2008-07-01 Tir Technology Lp System and method for controlling luminaires
US7494648B2 (en) * 2005-08-02 2009-02-24 Hoffmann-La Roche Inc. Cancerous disease modifying antibodies
US7456258B2 (en) 2005-08-02 2008-11-25 Arius Research, Inc. Cancerous disease modifying antibodies
US7452978B2 (en) 2005-08-02 2008-11-18 Arius Research, Inc. Cancerous disease modifying antibodies
US7456259B2 (en) 2005-08-02 2008-11-25 Arius Research, Inc. Cancerous disease modifying antibodies
US7452979B2 (en) 2005-08-02 2008-11-18 Arius Research, Inc. Cancerous disease modifying antibodies
US7411046B2 (en) 2005-08-02 2008-08-12 Arius Research Inc Cancerous disease modifying antibodies
US7420041B2 (en) * 2006-02-24 2008-09-02 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of TROP-2
CA2643063A1 (en) * 2006-02-24 2007-08-30 Arius Research, Inc. Cancerous disease modifying antibody 141205-02
WO2007095746A1 (en) 2006-02-24 2007-08-30 Arius Research Inc. Cancerous disease modifying antibodies
US20080305104A1 (en) * 2006-02-24 2008-12-11 Young David S F Cytotoxicity mediation of cells evidencing surface expression of TROP-2
US20080213267A1 (en) * 2006-02-24 2008-09-04 Arius Research, Inc. Cytotoxicity mediation of cells evidencing surface expression of TROP-2
US20080089891A1 (en) * 2006-07-26 2008-04-17 Arius Research, Inc. Cancerous disease modifying antibodies
AU2007321664A1 (en) * 2006-11-13 2008-05-22 F. Hoffmann-La Roche Ag Cancerous disease modifying antibodies
BRPI0718609A8 (pt) * 2006-11-13 2015-09-29 Arius Res Inc Anticorpos modificadores de doença cancerosa.
US8129502B2 (en) * 2006-11-13 2012-03-06 Hoffmann-La Roche Inc. Cancerous disease modifying antibodies
US8003761B2 (en) * 2007-01-23 2011-08-23 Hoffmann-La Roche Inc. Cancerous disease modifying antibodies
US20080206133A1 (en) * 2007-01-23 2008-08-28 Young David S F Cancerous Disease Modifying Antibodies
KR20090114454A (ko) * 2007-03-26 2009-11-03 에프. 호프만-라 로슈 아게 하이브리도마 세포주 ａｒ５１ａ６３０.３ 에 의해 생성된 암 질환 조절 항체 ０１０２０７－０１.
WO2008134876A1 (en) * 2007-05-07 2008-11-13 F. Hoffmann-La Roche Ag Cancerous disease modifying antibodies
EP2185718B1 (de) 2007-08-03 2017-10-04 MUSC Foundation For Research Development Menschliche monoklonale antikörper und verfahren zu ihrer herstellung
US20090191197A1 (en) * 2008-01-28 2009-07-30 Young David S F Cancerous disease modifying antibodies
US20090285751A1 (en) * 2008-04-10 2009-11-19 Young David S F Cancerous disease modifying antibodies
WO2009140754A1 (en) * 2008-05-19 2009-11-26 F. Hoffmann-La Roche Ag An anti-cancer cytotoxic monoclonal antibody
CA2731129A1 (en) * 2008-07-17 2010-01-21 Helen P. Findlay Cancerous disease modifying antibodies
WO2011004899A1 (en) 2009-07-06 2011-01-13 Takeda Pharmaceutical Company Limited Cancerous disease modifying antibodies
US8541646B2 (en) 2009-10-06 2013-09-24 Regeneron Pharmaceuticals, Inc. Genetically modified mice and engraftment
KR102109172B1 (ko) 2011-02-15 2020-05-12 리제너론 파마슈티칼스 인코포레이티드 인간화된 ｍ－ｃｓｆ 마우스
IL282472B2 (en) 2012-09-07 2024-04-01 Regeneron Pharma Genetically modified non-human animals and methods of their use
SG10201707449TA (en) 2012-11-05 2017-10-30 Regeneron Pharma Genetically modified non-human animals and methods of use thereof
ES2854276T3 (es) 2014-05-19 2021-09-21 Regeneron Pharma Animales no humanos modificados genéticamente que expresan EPO humana
WO2016168212A1 (en) 2015-04-13 2016-10-20 Regeneron Pharmaceuticals, Inc. Humanized sirpa-il15 knockin mice and methods of use thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5780327A (en) * 1980-11-05 1982-05-19 Toyobo Co Ltd Carcinostatic agent
EP0322240B1 (de) * 1987-12-23 1995-03-01 The Board Of Trustees Of The Leland Stanford Junior University Schimäre immunkompromittierende Säugetiere und ihre Verwendung
JPH01202295A (ja) * 1988-02-05 1989-08-15 Eisai Co Ltd 抗ｈｄモノクロナール抗体及びその製法
JPH01216267A (ja) * 1988-02-25 1989-08-30 Shinotesuto Kenkyusho:Kk Ｈｄ抗原の酵素免疫測定法
EP0438053B1 (de) * 1990-01-15 1999-06-16 Yeda Research And Development Company Limited Dauerhafte Verpflanzung und Entwicklung menschlicher hämatopoietischer Zellinien bei normalen Säugetieren
JPH03240498A (ja) * 1990-02-16 1991-10-25 Nobuyoshi Shimizu 抗体およびそれを使用した免疫分析方法
CA2063408A1 (en) * 1990-05-03 1991-11-04 Susan Mayo Human lymphoid tissue in an immunocompromised host
WO1991018615A1 (en) * 1990-05-25 1991-12-12 Systemix, Inc. Human peripheral blood cells in an immunocompromised host
EP0491057B1 (de) * 1990-07-10 1998-12-30 Nkk Corporation Geflügelspezifischen immunglobulin g produzierende hybridomas
WO1993005796A1 (en) * 1991-09-19 1993-04-01 The Scripps Research Institute Method for producing human antibodies in a non-human animal, and animals therefor

Also Published As

Publication number Publication date
US5869268A (en) 1999-02-09
US5681729A (en) 1997-10-28
EP0539970B1 (de) 1999-05-26
EP0539970A2 (de) 1993-05-05
DE69229254D1 (de) 1999-07-01
EP0539970A3 (en) 1994-05-25

Similar Documents

Publication Publication Date Title
DE69229254T2 (de) Verfahren zur Herstellung von menschlichen Lymphozyten und menschlichen Antikörpern; und so hergestellte Antikörper
DE69322094D1 (de) Heterogene membrane und verfahren zur herstellung
DE69126762T2 (de) Biologisches Verfahren zur Herstellung von Alpha-Hydroxyamid und Alpha-Hydroxysäure
DE68912909D1 (de) Verfahren zur Herstellung von Nitrilen und Oxiden.
DE69310669D1 (de) Prozess und Vorrichtung zur Herstellung von Allylchlorid
DE68927949T2 (de) 3,9-Diphosphaspiroundecane und Verfahren zur Herstellung von 3,9-Diphosphaspiroundecanen
DE69311817D1 (de) Verfahren zur Herstellung von Kohle-Kohle-Verbund-Vorformen und Kohle-Kohle-Verbund
ATA111789A (de) Humaner monoklonaler antikörper und hybridom zur herstellung desselben
DE68928619T2 (de) Verfahren zur Herstellung von mono-N-alkylierten Polyazamacrocyclen
DE69220113D1 (de) Verfahren zur Herstellung von menschlichem Serum Albumin
DE59606485D1 (de) Verfahren zur Herstellung von Poly-o-hydroxyamiden und Poly-o-mercaptoamiden
DE69214750T2 (de) Verfahren zur Herstellung von Tribromstyrol und beta-Bromethyltribrombenzol
DE69028820T2 (de) Vorrichtung zur Herstellung von Kunststoffbeuteln und entsprechende Herstellungsmethode
DE59606489D1 (de) Verfahren zur Herstellung von Poly-o-hydroxyamiden und Poly-o-mercaptoamiden
DE69508151D1 (de) Verfahren zur Herstellung von Verbundfolie und Verbundfolie
DE59606657D1 (de) Verfahren zur Herstellung von Poly-o-hydroxyamiden und Poly-o-mercaptoamiden
DE69424503D1 (de) Verfahren zur Herstellung von Dimethylchlorsilan und Triorganochlorsilan
DE59606488D1 (de) Verfahren zur Herstellung von Poly-o-hydroxyamiden und Poly-o-mercaptoamiden
DE68929433T2 (de) Verfahren zur Herstellung von JFET-Transistoren und Kondensatoren
DE68913779D1 (de) D-Amidase und Verfahren zur Herstellung von D-alpha-Alanin und/oder L-alpha-Alaninamid.
DE68927119D1 (de) Verfahren zur Herstellung von 4-Hydroxypyrimidin
DE59206187D1 (de) Verfahren zur Herstellung von 4-Alkylsulfonyl-1-alkyl-2-chlorbenzolen und Zwischenprodukte
DE59607034D1 (de) Verfahren zur Herstellung von Poly-o-hydroxyamiden und Poly-o-mercaptoamiden
DE4294717T1 (de) Verfahren zur Herstellung von medizinischen Beuteln
DE69212782T2 (de) Verfahren zur Herstellung von Polyaminen und Polyisocyanaten

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee